Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions

doi:10.2147/CMAR.S265828

IMR OpenIR

	Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
	Zeng, Guoming 1,2; Jin, Libo 3,4,5; Ying, Qinsi 6; Chen, Haojie 3; Thembinkosi, Murinda Charmaine 3; Yang, Chunguang 7; Zhao, Jinlong 7; Ji, Hao 3; Lin, Sue 3; Peng, Renyi 3; Zhang, Maolan 1,3; Sun, Da 3
通讯作者	Zhang, Maolan(zml@cqu.edu.cn) ; Sun, Da(sunday@wzu.edu.cn)
	2020
发表期刊	CANCER MANAGEMENT AND RESEARCH
ISSN	1179-1322
卷号	12 页码:10411-10421
摘要	Cancer immunotherapy is a promising approach that has recently gained its importance in treating cancer. Despite various approaches of immunotherapies being used to target cancer cells, they are either not effective against all types of cancer or for all patients. Although efforts are being made to improve the cancer immunotherapy in all possible ways, one important hindrance that lowers the immune response to kill cancer cells is the infiltration of Regulatory T (Treg) cells into the tumor cells, favoring tumor progression, on one hand, and inhibiting the activation of T cells to respond to cancer cells, on the other hand. Therefore, new anti-cancer drugs and vaccines fail to show promising results against cancer. This is due to the infiltration of Treg cells into the tumor region and suppression of anti-cancer activity. Thus, regardless of various types of immunotherapies being practiced, understanding the mechanisms of how Treg cells favor tumor progression and inhibition of anti-cancer activity is worthwhile. Therefore, the review highlights the importance of Tregs cells and how depletion of Treg cells can pave the way to an effective immunotherapy by activating the immune responses against cancer.
关键词	cancer immunotherapy Treg cells FoxP3 targeting Treg cells anti-cancer
资助者	Natural Science Foundation of Zhejiang Province ; National Natural Science Foundation of China ; Shenzhen Science and Technology Research Funding ; Special project of basic research and frontier exploration in Chongqing
DOI	10.2147/CMAR.S265828
收录类别	SCI
语种	英语
资助项目	Natural Science Foundation of Zhejiang Province[Q19E010021] ; Natural Science Foundation of Zhejiang Province[LQ20C020003] ; Natural Science Foundation of Zhejiang Province[LQ20C200015] ; National Natural Science Foundation of China[51901160] ; National Natural Science Foundation of China[51808086] ; Shenzhen Science and Technology Research Funding[JCYJ20160608153641020] ; Special project of basic research and frontier exploration in Chongqing[cstc2018jcyjAX0078]
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000579720000004
出版者	DOVE MEDICAL PRESS LTD
引用统计	被引频次：13[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.imr.ac.cn/handle/321006/140957
专题	中国科学院金属研究所
通讯作者	Zhang, Maolan; Sun, Da
作者单位	1.Chongqing Univ Sci & Technol, Chongqing 401331, Peoples R China 2.China Met Construct Engn Grp Co Ltd, Chongqing 400044, Peoples R China 3.Wenzhou Univ, Inst Life Sci, Higher Educ Pk, Wenzhou 325035, Zhejiang, Peoples R China 4.Biomed Collaborat Innovat Ctr Zhejiang Prov, Wenzhou 325035, Zhejiang, Peoples R China 5.Biomed Collaborat Innovat Ctr Wenzhou, Engn Lab Zhejiang Prov Pharmaceut Dev Growth Fact, Wenzhou 325035, Zhejiang, Peoples R China 6.Univ Chinese Acad Sci, Wenzhou Inst, Wenzhou 325035, Zhejiang, Peoples R China 7.Chinese Acad Sci, Inst Met Res, Shenyang 110016, Liaoning, Peoples R China
推荐引用方式 GB/T 7714	Zeng, Guoming,Jin, Libo,Ying, Qinsi,et al. Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions[J]. CANCER MANAGEMENT AND RESEARCH,2020,12:10411-10421.
APA	Zeng, Guoming.,Jin, Libo.,Ying, Qinsi.,Chen, Haojie.,Thembinkosi, Murinda Charmaine.,...&Sun, Da.(2020).Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions.CANCER MANAGEMENT AND RESEARCH,12,10411-10421.
MLA	Zeng, Guoming,et al."Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions".CANCER MANAGEMENT AND RESEARCH 12(2020):10411-10421.